HUE043194T2 - PLK-4 inhibitor sója és kristályformái - Google Patents

PLK-4 inhibitor sója és kristályformái

Info

Publication number
HUE043194T2
HUE043194T2 HUE14854037A HUE14854037A HUE043194T2 HU E043194 T2 HUE043194 T2 HU E043194T2 HU E14854037 A HUE14854037 A HU E14854037A HU E14854037 A HUE14854037 A HU E14854037A HU E043194 T2 HUE043194 T2 HU E043194T2
Authority
HU
Hungary
Prior art keywords
plk
inhibitor
salt
crystalline forms
crystalline
Prior art date
Application number
HUE14854037A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Brent Sampson
Miklos Feher
Heinz W Pauls
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of HUE043194T2 publication Critical patent/HUE043194T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14854037A 2013-10-18 2014-10-17 PLK-4 inhibitor sója és kristályformái HUE043194T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18

Publications (1)

Publication Number Publication Date
HUE043194T2 true HUE043194T2 (hu) 2019-08-28

Family

ID=52827507

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14854037A HUE043194T2 (hu) 2013-10-18 2014-10-17 PLK-4 inhibitor sója és kristályformái

Country Status (27)

Country Link
US (5) US9884855B2 (enExample)
EP (1) EP3057965B1 (enExample)
JP (1) JP6492072B2 (enExample)
KR (3) KR102395737B1 (enExample)
CN (2) CN105764899B (enExample)
AU (1) AU2014336929B9 (enExample)
CA (1) CA2926845C (enExample)
CY (1) CY1121484T1 (enExample)
DK (1) DK3057965T3 (enExample)
EA (1) EA031569B1 (enExample)
ES (1) ES2718603T3 (enExample)
HR (1) HRP20190564T1 (enExample)
HU (1) HUE043194T2 (enExample)
IL (1) IL245038B (enExample)
LT (1) LT3057965T (enExample)
ME (1) ME03377B (enExample)
MX (1) MX359069B (enExample)
NZ (1) NZ718744A (enExample)
PL (1) PL3057965T3 (enExample)
PT (1) PT3057965T (enExample)
RS (1) RS58413B1 (enExample)
SG (1) SG11201602783SA (enExample)
SI (1) SI3057965T1 (enExample)
SM (1) SMT201900124T1 (enExample)
TR (1) TR201902875T4 (enExample)
TW (1) TWI659952B (enExample)
WO (1) WO2015054793A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
TR201902875T4 (tr) 2013-10-18 2019-03-21 Univ Health Network Plk-4 inhibitörünün tuz ve kristal formları.
JP7343483B2 (ja) * 2017-09-08 2023-09-12 ユニバーシティー ヘルス ネットワーク Polo様キナーゼ4の阻害のための併用療法
EP3959209A4 (en) 2019-04-24 2022-12-28 University Health Network S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE
KR20220124177A (ko) * 2019-12-06 2022-09-13 유니버시티 헬스 네트워크 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법
PE20231656A1 (es) * 2020-11-02 2023-10-17 Trethera Corp Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
TWI926033B (zh) 2021-05-11 2026-05-21 美商歐瑞克製藥公司 類polo激酶4抑制劑

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
WO2008118097A1 (en) * 2007-03-23 2008-10-02 Agency For Science, Technology And Research Palladium catalysts
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
WO2010125004A1 (en) 2009-04-29 2010-11-04 Nerviano Medical Sciences S.R.L. Cdk inhibitor salts
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
CA2803446C (en) 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
EP2766352B1 (en) * 2011-10-12 2018-06-06 University Health Network (UHN) Indazole compounds as kinase inhibitors and method of treating cancer with same
EA030089B1 (ru) 2013-10-18 2018-06-29 Юниверсити Хелс Нетуорк Лечение рака поджелудочной железы
TR201902875T4 (tr) 2013-10-18 2019-03-21 Univ Health Network Plk-4 inhibitörünün tuz ve kristal formları.

Also Published As

Publication number Publication date
RS58413B1 (sr) 2019-04-30
US10392374B2 (en) 2019-08-27
US10919886B2 (en) 2021-02-16
US11667627B2 (en) 2023-06-06
NZ718744A (en) 2021-07-30
TW201609717A (zh) 2016-03-16
WO2015054793A1 (en) 2015-04-23
LT3057965T (lt) 2019-03-12
SMT201900124T1 (it) 2019-05-10
HRP20190564T1 (hr) 2019-05-17
US20210269428A1 (en) 2021-09-02
TWI659952B (zh) 2019-05-21
MX359069B (es) 2018-09-12
US20190248775A1 (en) 2019-08-15
US10472353B2 (en) 2019-11-12
PT3057965T (pt) 2019-04-23
AU2014336929B2 (en) 2018-11-22
EP3057965B1 (en) 2019-01-02
JP6492072B2 (ja) 2019-03-27
CY1121484T1 (el) 2020-05-29
JP2016537326A (ja) 2016-12-01
TR201902875T4 (tr) 2019-03-21
KR20160070106A (ko) 2016-06-17
ES2718603T3 (es) 2019-07-03
EP3057965A4 (en) 2017-05-24
US20200140428A1 (en) 2020-05-07
US20160264559A1 (en) 2016-09-15
PL3057965T3 (pl) 2019-08-30
IL245038B (en) 2019-11-28
EA201690755A1 (ru) 2016-09-30
ME03377B (me) 2020-01-20
CA2926845C (en) 2023-06-13
US20180155335A1 (en) 2018-06-07
CA2926845A1 (en) 2015-04-23
SI3057965T1 (sl) 2019-04-30
CN105764899A (zh) 2016-07-13
KR20210137251A (ko) 2021-11-17
KR20220063299A (ko) 2022-05-17
EP3057965A1 (en) 2016-08-24
CN113248486A (zh) 2021-08-13
EA031569B1 (ru) 2019-01-31
IL245038A0 (en) 2016-05-31
SG11201602783SA (en) 2016-05-30
AU2014336929B9 (en) 2019-03-21
MX2016004963A (es) 2016-06-28
DK3057965T3 (en) 2019-04-01
CN105764899B (zh) 2021-06-01
US9884855B2 (en) 2018-02-06
KR102395737B1 (ko) 2022-05-10

Similar Documents

Publication Publication Date Title
IL267681B (en) Selective grp94 inhibitors and uses thereof
HUE057734T2 (hu) Heterociklusos vegyületek és alkalmazásuk
HUE040434T2 (hu) Szelektív CDK4/6 inhibitor szilárd alakjai
IL240967A0 (en) Inhibitors of the kynurenine pathway
SMT201700363T1 (it) Inibitori di bromodominio cristallini
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3290407T (lt) Bromodomeno inhibitoriai
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
DK3043785T3 (da) Anvendelse af r-ketamin og salt deraf som lægemidler
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
HUE042466T2 (hu) Eljárás és köztitermékek JAK inhibitor elõállítására
HUE046285T2 (hu) Omecamtiv mecarbil sói és eljárás a só elõállítására
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
HUE053047T2 (hu) MDM2 inhibitor kristályos formája
SI3293176T1 (sl) Kristalna oblika inhibitorja PDE4
DK2958926T3 (da) Epidithiodioxopiperazinforbindelse eller derivater deraf og anvendelse deraf
EP3071554A4 (en) Crystalline forms of lesinurad and its sodium salt
IL245038B (en) Salt and crystal forms of plk–4 inhibitor
HUE056048T2 (hu) Helyettesített pirimidin vegyületek és SYK inhibitorként való alkalmazásuk
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
DK3074139T3 (da) Bruserenhed med brusehovedhus
TH1401007310A (th) เอไมด์ของสารประกอบ 2-อะมิโน-4-เอริลไธอะโซลและเกลือของสารประกอบดังกล่าว
TH1501001781A (th) สารประกอบเตตระโซลิโนน และการใช้ของสิ่งนั้น
TH1501001044A (th) เกลือแอมีน และผลึกของสารนั้น